In response to the second question at the end of the conference presentation, I think Spiro said that no clear mutational pathway has been identified for Sapacitabine in NSCLC but it appears that sapacitabine works against mutations along a homologous recombination pathway and there will be a press release in a few days.
Did anyone hear what was said more clearly?
There is information regarding the homologous recombination pathway a on the website. http://www.cyclacel.com/cyc/rd/publications/abstract3502.pdf
I am, just not all of it and not at a price you're hoping for in a near term buyout. It's called the open market.
All kidding aside, early stage biopharma major investors are very possibly looking at CYCC now or more likely have them on their radar as and if clinical trial data evolves favorably over time for them to consider a move on the company.
Hopefully, CYCC management is as confident in their drugs as I think they are and therefore their level of interest in selling out now I think is non-existent.
If the pps over the next year or 2 gets above $10-15 per share, that could change the mindset of management. Not that I think they would be willing to sell at that price, as long as data remains favorable, but it would be at a price point that could lead to an acceptable price for them and it certainly would be a much higher price than could be negotiated now.
I agree, it's not mgt's plan to pursue a buyout. Someone would have to force them to do it. It wouldn't be the preferred shareholders...it would come from the common shareholders. Either someone who is disenchanted - or a new investor who has done the math and realizes there could be a huge and QUICK windfall profit.
Sure, I'd prefer a $1 million profit in 3 years vs. $100,000 today - but I'd vote for a buyout given the opportunity. That's because I don't have any profit today.
the thought of a buyout now is such a huge negative for me. while I'd take the price they could sell it for now, I can't stand the thought of giving up what could easily happen to the pps in the next 2-4 years. This risk/reward opportunity comes across once in a lifetime.
The fact that the preferred shareholders didn't even get enough participation to vote in two new board members strongly suggests to me that most of the preferred shareholders are happy with current management. This is precisely the opposite of what the seeking alpha guy said recently about the preferred shareholders and how with the 2 new board members they might push for a buy out.
It certainly seems like management has zero interest in selling the company now, which makes perfect sense. After all these years they are finally moving relatively close to getting FDA approval and getting the drug to the market with AML It would be a shocker to me if management is willing to sell now for what could amount to a token price, compared to where the stock probably will be when we get closer to AML fda approval and not remotely close to where the pps should be upon ultimate approval, and that's just for one indication.
The only reason for the company to want to sell now is that they think their pipeline of drugs are much less likely to be successful than everything we have read about them to date, which I highly doubt is the case.
I wonder also if someone will force their hand. If the stock price sinks any lower, I think shareholder dissatisfaction will be increasing. It wouldn't take much to buy control of the company. Somebody could sell all the rights separately or the company as a whole and make a bundle.
Yes, based on the funding this week that is exactly what I'm thinking.
It makes sense. They now have the money for AML and if they keep that to themselves, they will reap all the profits if and when it gets approved. They can then make a partnerhsip in the areas that they don't have the money to easily go forward.
I have no insite other than my own logic so just like I didn't expect this week's funding, I obviously could be wrong on this.
But I am convinced that they are still pursuing a partnerhsip and however it ends up, it will probably be good for the company and therefore will be good for us shareholders, even if the partnership concept is different than what I'm thinking now.
Are you thinking that CYCC will keep sapacitabine for AML (and maybe MDS) all to itself - and then they'll partner on seliciclib and other uses of sapacitabine?
If that's the case, the stock should be off to the races on news like that.